Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine

10/21/2021 | 06:45am EST

Pfizer Inc. and BioNTech SE announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-?g booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age and older. In the trial, a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series restored vaccine protection against COVID-19 to the high levels achieved after the second dose, showing a relative vaccine efficacy of 95.6% when compared to those who did not receive a booster. These are the first efficacy results from any randomized, controlled COVID-19 vaccine booster trial. All trial participants previously completed the primary two-dose series of the Pfizer-BioNTech vaccine, and then were randomized 1:1 to receive either a 30-?g booster dose (the same dosage strength as those in the primary series) or placebo. The median time between second dose and administration of the booster dose or placebo was approximately 11 months. Symptomatic COVID-19 occurrence was measured from at least 7 days after booster or placebo, with a median follow-up of 2.5 months. During the study period, there were 5 cases of COVID-19 in the boosted group, and 109 cases in the non-boosted group. The observed relative vaccine efficacy of 95.6% (95% CI: 89.3, 98.6) reflects the reduction in disease occurrence in the boosted group versus the non-boosted group in those without evidence of prior SARS-CoV-2 infection. Median age of participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% of participants 65 years and older. Multiple subgroup analyses showed efficacy was consistent irrespective of age, sex, race, ethnicity, or comorbid conditions. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no safety concerns identified. Pfizer and BioNTech plan to submit detailed results from the trial for peer-reviewed publication. The companies also plan to share these data with the U.S. Food and Drug Administration, European Medicines Agency, and other regulatory agencies around the world as soon as possible. The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech?s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.


ę S&P Capital IQ 2021
All news about PFIZER, INC.
07:00aHow worried should we be about the Omicron variant?
RE
01:10aPARENTING IN A PANDEMIC : To Vaccinate Or Not To Vaccinate?
AQ
11/26ADRs Close Lower; BioNTech Rises, Carnival Drops
DJ
11/26US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New COVID-19 Stra..
MT
11/26CLOSE UPDATE : US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New C..
MT
11/26FTSE 100 Closes Friday Down as Latest Coronavirus Variant Sparks Sell-off
DJ
11/26Covid-19 Vaccine Maker Stocks Higher Amid Variant Concerns
DJ
11/26New purchase in the MarketScreener USA Portfolio
11/26FDA Places Clinical Hold on Phase 3 Study for Ocugen COVID-19 Vaccine Covaxin
MT
11/26Pfizer Up Over 6%, on Track for Record High Close -- Data Talk
DJ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 529 M - -
Net income 2021 21 354 M - -
Net Debt 2021 27 827 M - -
P/E ratio 2021 13,9x
Yield 2021 2,92%
Capitalization 303 B 303 B -
EV / Sales 2021 4,06x
EV / Sales 2022 3,97x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 54,00 $
Average target price 48,53 $
Spread / Average Target -10,1%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.46.70%303 095
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049
ABBVIE INC.8.74%205 976